Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Change in Accured Expenses (2017 - 2025)

Crinetics Pharmaceuticals (CRNX) has 9 years of Change in Accured Expenses data on record, last reported at $11.2 million in Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 82.73% year-over-year to $11.2 million; the TTM value through Dec 2025 reached $29.0 million, up 117.64%, while the annual FY2025 figure was $29.0 million, 117.64% up from the prior year.
  • Change in Accured Expenses reached $11.2 million in Q4 2025 per CRNX's latest filing, up from $6.6 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $12.5 million in Q2 2025 and bottomed at -$1.4 million in Q1 2025.
  • Average Change in Accured Expenses over 5 years is $3.6 million, with a median of $3.0 million recorded in 2021.
  • Peak YoY movement for Change in Accured Expenses: tumbled 369.23% in 2022, then surged 866.13% in 2025.
  • A 5-year view of Change in Accured Expenses shows it stood at $3.9 million in 2021, then increased by 4.75% to $4.1 million in 2022, then plummeted by 53.47% to $1.9 million in 2023, then skyrocketed by 221.89% to $6.1 million in 2024, then soared by 82.73% to $11.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $11.2 million in Q4 2025, $6.6 million in Q3 2025, and $12.5 million in Q2 2025.